Evon Poon

Institute of Cancer Research

United Kingdom

Research Interests

Explore related searches

Professors in United Kingdom Professors in Cancer Biology Cancer Biology professors in United Kingdom

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

Articles (12)

Year:

2024

Year:

2024

Year:

2023

Year:

2022

Year:

2022

Year:

2021

Year:

2021

Year:

2020

Year:

2020

Year:

2020

Year:

2020

Year:

2020

Collaborators (16)

Behnam Nabet

Assistant Professor

Fred Hutchinson Cancer Research Center

UNITED STATES

View details

Emma Vincent

University of Bristol

UNITED KINGDOM

View details

Igor Vivanco

King’s College London

UNITED KINGDOM

View details

Mark Richards

University of Leeds

UNITED KINGDOM

View details

Peter Andrews

University of Sheffield

UNITED KINGDOM

View details

William Anderson

University College London

UNITED KINGDOM

View details

Martin Eilers

Professor

University of Würzburg

GERMANY

View details

ROBERTO TONELLI

Assistant professor

University of Bologna

ITALY

View details

Gabriel Valbuena

University of Oxford

UNITED KINGDOM

View details

Jessica Boult

Institute of Cancer Research

UNITED KINGDOM

View details

Patrick Woster

Distinguished University Professor, Chair and SmartState® Endowed Chair in Drug Discovery

Medical University of South Carolina

UNITED STATES

View details

Kazuhiro Koikawa

Beth Israel Deaconess Medical Center

UNITED STATES

View details

Nicholas Jones

Swansea University

UNITED KINGDOM

View details

Martin Distel

Associate Professor

University of Utah

UNITED STATES

View details

Anestis Tsakiridis

UNITED KINGDOM

View details

Ivana Barbaric

Lecturer

University of Sheffield

UNITED KINGDOM

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Evon Poon

Research Interests

Explore related searches

Contact this professor

Articles (12)

A human neural crest model reveals the developmental impact of neuroblastoma-associated chromosomal aberrations

Spliceosomal vulnerability of MYCN-amplified neuroblastoma is contingent on PRMT5-mediated regulation of epitranscriptomic and metabolomic pathways

Combination Therapies Targeting ALK-aberrant Neuroblastoma in Preclinical Models

The biguanide polyamine analog verlindamycin promotes differentiation in neuroblastoma via induction of antizyme

Indisulam targets RNA splicing and metabolism to serve as a therapeutic strategy for high-risk neuroblastoma

Sulfopin is a covalent inhibitor of Pin1 that blocks Myc-driven tumors in vivo

Combined inhibition of Aurora-A and ATR kinases results in regression of MYCN-amplified neuroblastoma

Noninvasive MRI Native T1 Mapping Detects Response to MYCN-targeted Therapies in the Th-MYCN Model of Neuroblastoma

Orally bioavailable CDK9/2 inhibitor shows mechanism-based therapeutic potential in MYCN-driven neuroblastoma.

Orally bioavailable CDK9/2 inhibitor shows mechanism-based therapeutic potential in MYCN-driven neuroblastoma

Accelerating drug development for neuroblastoma: Summary of the Second Neuroblastoma Drug Development Strategy forum from Innovative Therapies for Children with Cancer and International Society of Paediatric Oncology Europe Neuroblastoma.

MYCN expression induces replication stress and sensitivity to PARP inhibition in neuroblastoma.

Collaborators (16)

Behnam Nabet

Emma Vincent

Igor Vivanco

Mark Richards

Peter Andrews

William Anderson

Martin Eilers

ROBERTO TONELLI

Gabriel Valbuena

Jessica Boult

Patrick Woster

Kazuhiro Koikawa

Nicholas Jones

Martin Distel

Anestis Tsakiridis

Ivana Barbaric

Make your next move.